Regulatory Submission & Approval
This phase converts years of evidence into the regulated artefact on which approval turns: a marketing application for a medicine, a conformity-assessment technical file or premarket submission for a device, the registration dossiers other industries require. For medicines, the quality module tells the CMC story — development per ICH Q8 and Q11, specifications justified under ICH Q6A or, for biologicals, Q6B, stability under Q1A(R2) — while the clinical modules carry study reports structured per ICH E3. For devices, the technical documentation under the EU MDR assembles design, risk management, clinical evaluation, and manufacturing evidence for a notified body or regulator. The dossier is not a records dump: it is an argument, and every number in it must trace to a source record somewhere in the organisation's systems.
What this page does not claim
Phases are an organising device, not a regulatory mandate — real programmes overlap them, and a medical device, a food product and a small-molecule drug traverse them differently. Each page says where the differences bite.
What happens in this phase
This phase converts years of evidence into the regulated artefact on which approval turns: a marketing application for a medicine, a conformity-assessment technical file or premarket submission for a device, the registration dossiers other industries require. For medicines, the quality module tells the CMC story — development per ICH Q8 and Q11, specifications justified under ICH Q6A or, for biologicals, Q6B, stability under Q1A(R2) — while the clinical modules carry study reports structured per ICH E3. For devices, the technical documentation under the EU MDR assembles design, risk management, clinical evaluation, and manufacturing evidence for a notified body or regulator. The dossier is not a records dump: it is an argument, and every number in it must trace to a source record somewhere in the organisation's systems.
The phase is interactive, not postal. Agencies raise questions — deficiency letters, requests for information, major objections — on clocks that stop and restart, and answering them well requires the same traceability as the original dossier, at speed. Pre-approval and pre-licence inspections test whether the facilities and records match what the application claims; a mismatch between the dossier and the shop floor is among the most damaging findings available. Meanwhile ICH Q12 gives sponsors a vocabulary for what comes after: established conditions — the elements of the application that are binding, such that changing them later requires a regulatory transaction — and post-approval change management protocols that pre-agree how foreseeable changes will be made.
Quality's ownership here is the integrity of the claim. Regulatory affairs assembles and negotiates; quality assures that what is asserted is true, sourced, and sustainable — that the process described is the process validated, that the specifications filed are the specifications the laboratory tests against, and that commitments made under questioning are captured, tracked, and discharged. The registered details that emerge from approval become the reference manufacturing must match for the product's commercial life, which is why the regulatory information system that holds them is a controlled, validated system and not a filing cabinet.
- A complete evidence package — quality, nonclinical, clinical — with every claim traceable to an approved source record.
- A defined regulatory strategy: pathway, jurisdictions, and the sequencing of submissions and inspections.
- Manufacturing and testing operations in a demonstrable state of control, ready for pre-approval or pre-licence inspection.
- A submission-management capability — publishing, lifecycle tracking, commitment management — under validated control.
- Marketing authorisation, clearance, approval, or certification granted, with its conditions and commitments explicitly captured.
- The registered details — process, specifications, sites, shelf-life — recorded as the binding reference for manufacturing and change control.
- All agency questions answered and closed, with the answers reconciled into the dossier of record.
- Post-approval commitments logged with owners and dates, feeding the systems that will discharge them.
SPEQ synthesis. Phase boundaries and gate criteria are an organising device for planning and review, not a regulatory mandate. Real programmes overlap phases and re-enter them; treat these as the questions worth answering, not a compliance checklist.
- Assure dossier-to-reality parity: what the application says is what the site does, before an inspector tests the difference.
- Host and manage pre-approval and pre-licence inspections, including the readiness work that precedes them.
- Control the commitment ledger — every promise made to an agency captured, owned, and tracked to discharge.
- Govern the identification of established conditions under ICH Q12, so the organisation knows which changes trigger regulatory transactions.
- Verify that responses to agency questions are sourced from controlled records, not drafted from memory under deadline pressure.
- The submitted dossier or technical documentation, under version control as the dossier of record
- Agency correspondence, questions, and the sourced responses to them
- Pre-approval / pre-licence inspection records and their commitments
- The approval instrument and its conditions — licence, clearance, certificate
- The registered-details record that manufacturing and change control will be held to
- The post-approval commitment ledger with owners and due dates
- Dossier drift: the filed process and the operated process diverge during the review period, and the pre-approval inspection finds the gap.
- Commitments made in responses under time pressure, never entered into any tracking system, rediscovered by the agency years later.
- Established conditions never explicitly identified, so every post-approval change becomes a debate about whether it needed approval.
- Registered details held in documents rather than a controlled system, so different markets are quietly told different things.
- Treating the submission as regulatory affairs' private project, so quality discovers at approval what was promised on its behalf.
Derived from the 8 standards SPEQ maps to this phase, across 2 regulatory bodies: ICH, EC.
FREQUENTLY ASKED
What are "established conditions" and why do they matter?
Established conditions, defined by ICH Q12, are the elements of a marketing application that are legally binding — the parts a company cannot change without a regulatory transaction of some kind. Everything else in the dossier is supportive information, changeable under the firm's own quality system. The distinction matters because it converts post-approval change from a case-by-case argument into a managed framework: identify the established conditions explicitly, agree reporting categories for changing them, and — with a post-approval change management protocol — pre-agree how a foreseeable change will be evidenced and reported before it is needed.
What does a pre-approval inspection actually test?
Whether the application is true. An inspector arrives with the dossier and tests it against the facility: is the process described the process operated, are the batches cited real and their records intact, is the data in the submission traceable to raw data on site, and is the quality system capable of sustaining commercial manufacture. Data-integrity review is central — the submission batches' records, the laboratory's audit trails, the reconciliation between what was filed and what was found. A finding that the dossier and the site disagree is worse than either defect alone, because it impeaches the whole application.
How does device approval differ from drug approval?
Structurally. Most devices in Europe are not "approved" by a regulator at all: the manufacturer compiles technical documentation under the EU MDR, and a notified body assesses conformity and issues the certificate that permits CE marking — with the depth of scrutiny scaled to risk class. In the US, pathways range from premarket notification, resting on substantial equivalence, to premarket approval with full clinical evidence. The constant across both: the technical file is a living obligation, expected to stay current with the design, the risk file, and the post-market evidence for the device's entire life.